Ridgefield Acquisition Corp – ‘10KSB’ for 12/31/03

On:  Monday, 3/29/04, at 4:21pm ET   ·   For:  12/31/03   ·   Accession #:  926274-4-146   ·   File #:  0-16335

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report — Small Business   —   Form 10-KSB
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10KSB       Annual Report -- Small Business                       43    210K 
 2: EX-14       Material Foreign Patent                                2      9K 
 3: EX-31       Certification per Sarbanes-Oxley Act (Section 302)     2±     9K 
 4: EX-32       Certification per Sarbanes-Oxley Act (Section 906)     1      6K 

10KSB   —   Annual Report — Small Business
Document Table of Contents

10KSB
1st Page of 43
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2003

OR

 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                   .          
                    ----------------    ------------------

Commission File Number 0-16335

RIDGEFIELD ACQUISITION CORP.
 ---------------------------------------------------------
 (Name of Small Business Issuer as Specified in its Charter)

   Colorado                                         84-0922701
 -----------------------                            ------------------
(State or other juris-                               (IRS Employer  
   diction of incorpora-                             Identification No.)
tion or organization)                                             

 100 Mill Plain Road, Danbury, Connecticut 06877
 -----------------------------------------------------------
(Address of Principal Executive Offices)

Issuer's telephone number, including area code: (203) 791-3871                  

Securities registered under Section 12(g) of the Exchange Act:                  

$0.10 Par Value Common Stock
 ---------------------------
(Title of Class)

 10 South Street, Suite 202, Ridgefield, Connecticut 06877
------------------------------------------------
 (Former Address of Principal Executive Offices)

Check whether the issuer (1) filed all reports required to be filed by Section  
13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or
for such shorter period that the registrant was required to file such reports), 
and, (2) has been subject to such filing requirements for the past 90 days.     
                                           YES [X]  NO [ ]

Check if there is no disclosure of delinquent filers in response to Item 405 of 
Regulation S-K is not contained in this form, and no disclosure will be         
contained, to the best of registrant's knowledge, in definitive proxy or        
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB.     [X]                                   

The Issuer's revenues for fiscal year ended December 31, 2003, were $3,077.     

The aggregate market value of the Registrant's voting stock held, as of March   
22, 2004, by non-affiliates of the Registrant was $171,163.                     

As of March 22, 2004, Registrant had 813,028 shares of its $0.10 par value      
common stock outstanding.                                                       

Transitional Small Business Disclosure Format (check one):    Yes       No  X   
                                                                ---      ---

10KSB
2nd Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 2nd
PART I

ITEM 1.  DESCRIPTION OF BUSINESS.                                               

     Ridgefield Acquisition Corp. ("RAC" or the "Company") was incorporated as a
Colorado corporation on October 13, 1983 under the name OZO Diversified         
Automation, Inc. In March 1999, in connection with the sale of substantially all
of the Company's assets the Company changed its name to Bio-Medical Automation, 
Inc. On April 1, 2002, the Company was administratively dissolved by the        
Colorado Secretary of State for failing to timely file its bi-annual            
registration with the Colorado Secretary of State. On January 14, 2003 the      
Company filed an Application for Reinstatement pursuant to Section 7-114-203 of 
the Colorado Revised Statutes. In connection with the reinstatement, and in     
accordance with Colorado corporate law, the Company changed its name from       
Bio-Medical Automation, Inc. to Ridgefield Acquisition Corp. The reinstatement  
and name change became effective on January 14, 2003 when the Application for   
Reinstatement was filed with the Colorado Secretary of State. Neither the       
administrative dissolution nor reinstatement and name change has had or will    
have any material effect on the holders of the securities of the Company.       

  On March 9, 1999, the Company completed the sale of substantially all of
its assets to JOT Automation, Inc. (the "JOT Transaction"). As a result of the  
JOT Transaction, the Company's historical business, the depaneling and routing  
business, is considered to be a "discontinued operation" and, consequently,     
provides no benefit to persons seeking to understand the Company's financial    
condition or results of operations.                                             

Following the JOT Transaction the Company devoted its efforts to the  
development of a prototype micro-robotic device (the "micro-robotic device") to 
manipulate organic tissues on an extremely small scale. Due to the inability to 
complete the micro-robotic device, the Company determined that it would cease   
the development of the micro-robotic device and, as of June 30, 2000, the       
capitalized costs related to the patent underlying the micro-robotic device have
been written off by the Company. The Company has never derived any revenues from
the micro-robotic device.                                                       

Since July 2000, the Company has suspended all operations, except for 
necessary administrative matters relating to the timely filing of periodic      
reports as required by the Securities Exchange Act of 1934. Accordingly, during 
the period from January 1, 2003 through December 31, 2003 and the years ended   
December 31, 2002 and December 31, 2001, the Company has earned no revenues     
other than interest income from investments.                                    

Acquisition Strategy                                                            
--------------------                                                            

The Company is primarily engaged in seeking to arrange for a merger,  
acquisition, business combination or other arrangement by and between the       
Company and a viable operating entity. The Company has not identified a viable  
operating entity for a merger, acquisition, business combination or other       
arrangement, and there can be no assurance that the Company will ever           
successfully arrange for a merger, acquisition, business combination or other   
arrangement by and between the Company and a viable operating entity.           

1 

10KSB
3rd Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 3rd
   The Company anticipates that the selection of a business opportunity will
be a complex process and will involve a number of risks, because potentially    
available business opportunities may occur in many different industries and may 
be in various stages of development. Due in part to depressed economic          
conditions in a number of geographic areas, rapid technological advances being  
made in some industries and shortages of available capital, management believes 
that there are numerous firms seeking either the limited additional capital     
which the Company will have or the benefits of a publicly traded corporation, or
both. The perceived benefits of a publicly traded corporation may include       
facilitating or improving the terms upon which additional equity financing may  
be sought, providing liquidity for principal shareholders, creating a means for 
providing incentive stock options or similar benefits to key employees,         
providing liquidity for all shareholders and other factors.                     

    In some cases, management of the Company will have the authority to effect
acquisitions without submitting the proposal to the shareholders for their      
consideration. In some instances, however, the proposed participation in a      
business opportunity may be submitted to the shareholders for their             
consideration, either voluntarily by the Board of Directors to seek the         
shareholders' advice and consent, or because of a requirement of state law to do
so.                                                                             

    In seeking to arrange a merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity,           
management's objective will be to obtain long-term capital appreciation for the 
Company's shareholders. There can be no assurance that the Company will be able 
to complete any merger, acquisition, business combination or other arrangement  
by and between the Company and a viable operating entity.                       

The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable        
operating entity, although there is no assurance that the Company will be able  
to obtain such additional funds, if needed. Even if the Company is able to      
obtain additional funds there is no assurance that the Company will be able to  
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.                                                  

The Company's U.S. Patent                                                       
--------------------------                                                      

  Following the sale of substantially all of the Company's assets in 1999,
the Company devoted its efforts to the development of a prototype micro-robotic 
device (the "micro-robotic device") to manipulate organic tissues on an         
extremely small scale for microdissection. The Company filed a patent           
application in February 1998, to protect certain features of the system and     
method of the micro-robotic device. However, due to the inability of the Company
to complete the micro-robotic device, the Company determined that it would cease
development of the micro-robotic device and, as of June 30, 2000, the           
capitalized costs related to the patent underlying the micro-robotic device have
been written off by the Company.                                                

On March 19, 2002, the Company was awarded United States Patent No. US
6,358,749 B1 for the "Automated System for Chromosome Microdissection and Method
of Using Same" (the "Patent").                                                  

2 

10KSB
4th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 4th
 The Patent covers an automated system and method for microdissection of
samples such as chromosomes or other biological material, and in particular, it 
relates to a robotic assisted microdissection system and method that            
significantly reduces the time and skill needed for cellular and sub-cellular   
dissections. Microdissection is defined as dissection under the microscope;     
specifically: dissection of cells and tissues by means of fine needles that are 
precisely manipulated by levers. The system and method covered by the Patent    
attempts to provide reliability and ease of operation thereby making            
microdissection widely available to laboratories. While the Company has never   
derived any revenues from the micro-robotic device, the Company plans to attempt
to license or sell the technology covered by the Patent. There can be no        
assurances that the Company will be able to successfully market the technology  
covered by the Patent or that the Company will ever derive any revenues from the
Patent or the technology covered by the Patent.                                 

 During the first quarter of 2003, the Board of Directors of the Company
authorized the formation of a wholly owned subsidiary of the Company for the    
purposes of owning, developing and exploiting the Patent. On March 3, 2003, the 
Company filed Articles of Incorporation with the Secretary of State of the State
of Nevada to form Bio-Medical Automation, Inc., a Nevada corporation wholly     
owned by the Company (the "Subsidiary"). A copy of the Articles of Incorporation
of Bio-Medical Automation, Inc. a Nevada corporation are attached as an Exhibit 
to the Company's Current Report on Form 8-K filed on March 7, 2003 which is     
incorporated herein by reference. The Board of Directors of the Company has     
authorized management of the Company to transfer the Patent to the Subsidiary in
exchange for 5,000,000 shares of the common stock of the Subsidiary. The        
transfer of the Patent to the Subsidiary became effective in the quarter ended  
June 30, 2003. The Company plans to develop and exploit the Patent through the  
Subsidiary. There can be no assurances that the Subsidiary will successfully    
develop and/or exploit the technology covered by the Patent.                    

Investment Strategy                                                             
-------------------                                                             

  On August 25, 2003, the Board of Directors of the Company authorized the
Company to invest a portion of the Company's cash in marketable securities in an
effort to realize a greater rate of return than the Company is currently earning
in light of historically low interest rates. The Board directed that management 
maintain at least $40,000 of the Company's cash in a federally insured bank or  
money market account.                                                           

  In furtherance of the Company's investment strategy the Company opened a
brokerage account with Catalyst Financial LLC ("Catalyst"), a broker-dealer     
registered with the U.S. Securities and Exchange Commission and a member in good
standing with the National Association of Securities Dealers, Inc. Catalyst is  
owned and controlled by Steven N. Bronson, the Company's President. Catalyst has
agreed to charge the Company commissions of no more that $.02 per share with a  
minimum of $75 per trade on securities transactions. The Board approved the     
commission structure to be charged by Catalyst. Mr. Bronson abstained from      
voting on all Board resolutions concerning the Company's investment strategy and
the Company's arrangements with Catalyst.                                       

    On October 14, 2003, the Company deposited $250,000 in a brokerage account
with Catalyst. As of December 31, 2003, the Company owned securities value at   
$49,580 and an unrealized loss of $2,095). The Company's investment in          
securities is subject to all of the risks associated with equity investing,     
including a loss of monies invested. There can be no assurance that the Company 
will be able to obtain a profitable return on its investments.                  

3 

10KSB
5th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 5th
Employees                                                                       
---------                                                                       

      As of March 22, 2004, the Company had 1 employee, Steven N. Bronson,
who serves as the Company's President. The Company does not have any employees  
that are represented by a union or other collective bargaining group.           

Risk Factors Affecting Operating Results and Market Price of Stock              
------------------------------------------------------------------              

 Potential investors should carefully consider the risks described below
before making an investment decision concerning the common stock of the Company.
The risks and uncertainties described below are not the only ones we face. If   
any of the following risks actually occur, our business, financial condition or 
results of operations could be materially and adversely affected. In that case, 
the trading price of our common stock could decline, and investors may lose all 
or part of their investment.                                                    

The Company Has Limited Resources                                               
---------------------------------                                               

   The Company has limited resources and has had no revenues from operations
for the fiscal years ended December 31, 2003 and December 31, 2002. On March 9, 
1999, the Company sold substantially all of its assets and essentially ceased   
all operations. Currently, the primary source of revenue for the Company is     
interest income. The Company will only earn revenues through the acquisition of 
or merger with a target company (an "Acquisition") or through the Subsidiary's  
successful exploitation of the Patent. There can be no assurance that any target
company (a "Target"), at the time of the Company's consummation of an           
Acquisition of the Target, or at any time thereafter, will derive any material  
revenues from its operations or operate on a profitable basis, or that the      
Subsidiary will derive any revenues from the Patent. The current revenues of the
Company may not be sufficient to fund further Acquisitions or the successful    
development and exploitation of the Patent. Based on the Company's limited      
resources, the Company may not be able to effectuate its business plan and      
consummate an Acquisition or exploit the Patent. There can be no assurance that 
determinations ultimately made by the Company will permit the Company to achieve
its business objectives.                                                        

The Company Will Need Additional Financing in Order to Execute Its Business Plan
--------------------------------------------------------------------------------

The Company has had only nominal revenues to date and will be entirely
dependent upon its limited available financial resources to implement its       
business plan to complete an Acquisition or to derive any revenues from the     
Patent. The Company cannot ascertain with any degree of certainty the capital   
requirements for the execution of its business plan. In the event that the      
Company's limited financial resources prove to be insufficient to implement its 
business plan, the Company will be required to seek additional financing. In    
addition, in the event of the consummation of an Acquisition, the Company may   
require additional financing to fund the operations or growth of the Target. The
Company may also require additional financing to develop and exploit the Patent.

4 

10KSB
6th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 6th
Additional Financing May Not Be Available to the Company                        
--------------------------------------------------------                        

  There can be no assurance that additional financing will be available to
the Company on acceptable terms, or at all. To the extent that additional       
financing proves to be unavailable when needed, the Company would be limited in 
its attempts to complete Acquisitions and to successfully develop and exploit   
the Patent. The inability of the Company to secure additional financing, if     
needed, could also have a material adverse effect on the continued existence of 
RAC. The Company has no arrangements with any bank or financial institution to  
secure financing and there can be no assurance that any such arrangement, if    
required or otherwise sought, would be available on terms deemed to be          
commercially acceptable and in the best interests of the Company.               

The Company May Not Be Able to Borrow Funds                                     
-------------------------------------------                                     

     While there currently are no limitations on the Company's ability to borrow
funds, the limited resources of the Company and limited operating history will  
make it difficult to borrow funds. The amount and nature of any borrowings by   
the Company will depend on numerous considerations, including the Company's     
capital requirements, the Company's perceived ability to meet debt service on   
any such borrowings and the then prevailing conditions in the financial markets,
as well as general economic conditions. There can be no assurance that debt     
financing, if required or sought, would be available on terms deemed to be      
commercially acceptable by and in the best interests of the Company. The        
inability of the Company to borrow funds required to effect or facilitate an    
Acquisition may have a material adverse effect on the Company's financial       
condition and future prospects. Additionally, to the extent that debt financing 
ultimately proves to be available, any borrowings may subject the Company to    
various risks traditionally associated with indebtedness, including the risks of
interest rate fluctuations and insufficiency of cash flow to pay principal and  
interest. Furthermore, a Target may have already incurred borrowings and,       
therefore, the Company will be subjected to all the risks inherent thereto.     

Competition for Acquisitions                                                    
----------------------------                                                    

  The Company expects to encounter intense competition from other entities
having business objectives similar to those of the Company. Many of these       
entities, including venture capital partnerships and corporations, blind pool   
companies, large industrial and financial institutions, small business          
investment companies and wealthy individuals, are well-established and have     
extensive experience in connection with identifying and effecting Acquisitions  
directly or through affiliates. Many of these competitors possess greater       
financial, technical, human and other resources than the Company and there can  
be no assurance that the Company will have the ability to compete successfully. 
The Company's financial resources will be limited in comparison to those of many
of its competitors. This inherent competitive limitation may compel the Company 
to select certain less attractive acquisition prospects. There can be no        
assurance that such prospects will permit the Company to achieve its stated     
business objectives.                                                            

5 

10KSB
7th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 7th
The Company May Be Subject to                                                   
Uncertainty in the Competitive Environment of a Target                          
------------------------------------------------------                          

 In the event that the Company succeeds in effecting an Acquisition, the
Company will, in all likelihood, become subject to intense competition from     
competitors of the Target. In particular, certain industries which experience   
rapid growth frequently attract an increasingly large number of competitors,    
including competitors with greater financial, marketing, technical, human and   
other resources than the initial competitors in the industry. The degree of     
competition characterizing the industry of any prospective Target cannot        
presently be ascertained. There can be no assurance that, subsequent to a       
consummation of an Acquisition, the Company will have the resources to compete  
effectively in the industry of the Target, especially to the extent that the    
Target is in a high growth industry.                                            

The Company May Pursue an Acquisition With a Target Operating Outside the United
States: Special Additional Risks Relating to Doing Business in a Foreign Country
--------------------------------------------------------------------------------

      The Company may effectuate an Acquisition with a Target whose business
operations or even headquarters, place of formation or primary place of business
are located outside the United States. In such event, the Company may face the  
significant additional risks associated with doing business in that country. In 
addition to the language barriers, different presentations of financial         
information, different business practices, and other cultural differences and   
barriers that may make it difficult to evaluate such a Target, ongoing business 
risks may result from the internal political situation, uncertain legal systems 
and applications of law, prejudice against foreigners, corrupt practices,       
uncertain economic policies and potential political and economic instability    
that may be exacerbated in various foreign countries.                           

Uncertain Prospects of Technology Covered by Patent                             
---------------------------------------------------                             

    The Company has never derived any revenues from the technology
covered by the Patent and there can be no assurances that the Company or the    
Subsidiary will be able to derive any revenues from the exploitation of the     
Patent. The Company through the Subsidiary will attempt to research and develop 
a commercial application for the technology covered by the Patent. However there
can be no assurances that the Subsidiary will be able to find a commercial      
application for the technology covered by the Patent. Even if the Subsidiary is 
able to develop a commercial application for the technology covered by the      
Patent, there can be no assurances that the Subsidiary will be able to          
successfully market such application.                                           

6 

10KSB
8th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 8th
Competition for the Patent                                                      
--------------------------                                                      

 The Company expects to encounter competition from other entities in the
medical device business with technology similar to that covered by the Patent.  
Many of these entities, including large drug and medical companies,             
bio-technology companies, venture capital partnerships and corporations, blind  
pool companies, large industrial and financial institutions, small business     
investment companies and wealthy individuals, are well-established and have     
extensive experience in connection with developing and exploiting medical       
technology and devices. Many of these competitors possess greater financial,    
technical, human and other resources than the Company and there can be no       
assurance that the Company will have the ability to compete successfully. The   
Company's financial resources will be limited in comparison to those of many of 
its competitors. There can be no assurance that such prospects will permit the  
Company to achieve its stated business objectives.                              

Risks Associated with the Company's Investment Strategy                         
-------------------------------------------------------                         

      The Company's decision to invest a portion of its cash in marketable
securities exposes the Company to potential losses. The Company's investments in
marketable securities carry a risk of loss. While the Company will endeavor to  
invest in securities that have a potential for gain, there can be no assurances 
that the Company will not suffer losses based on its Investment Strategy.       

Steven N. Bronson is Critical to the Future Success of the Company              
------------------------------------------------------------------              

     Steven N. Bronson is the Chairman, C.E.O. and President of the Company. The
ability of the Company to successfully carry out its business plan and to       
consummate additional Acquisitions will be dependent upon the efforts of Mr.    
Bronson and the Company's directors. Notwithstanding the significance of Mr.    
Bronson, the Company has not obtained any "key man" life insurance on his life. 
The loss of the services of Mr. Bronson could have a material adverse effect on 
the Company's ability to successfully achieve its business objectives. If       
additional personnel are required, there can be no assurance that the Company   
will be able to retain such necessary additional personnel.                     

Mr. Bronson Has Effective Control of the Company's Affairs                      
----------------------------------------------------------                      

   Mr. Bronson beneficially owns and controls 734,160 shares of common stock
of the Company, including options to purchase 150,000 shares of common stock,   
representing approximately 76.2% of the issued and outstanding shares of common 
stock and approximately 76.2% of the voting power of the issued and outstanding 
shares of common stock of the Company. In the election of directors,            
stockholders are not entitled to cumulate their votes for nominees. Accordingly,
as a practical matter, Mr. Bronson may be able to elect all of the Company's    
directors and otherwise direct the affairs of the Company.                      

7 

10KSB
9th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 9th
There Exist Conflicts of Interest                                               
Relating to Mr. Bronson's Time Commitment to the Company                        
--------------------------------------------------------                        

   Mr. Bronson is not required to commit his full time to the affairs of the
Company. Mr. Bronson will have conflicts of interest in allocating management   
time among various business activities. As a result, the consummation of an     
Acquisition may require a greater period of time than if Mr. Bronson devoted his
full time to the Company's affairs. However, Mr. Bronson will devote such time  
as he deems reasonably necessary to carry out the business and affairs of the   
Company, including the evaluation of potential Targets and the negotiation and  
consummation of Acquisitions and, as a result, the amount of time devoted to the
business and affairs of the Company may vary significantly depending upon, among
other things, whether the Company has identified a Target or is engaged in      
active negotiation and consummation of an Acquisition.                          

There Exist Risks to Stockholders Relating to Dilution:                         
Authorization of Additional Securities and                                      
Reduction of Percentage Share Ownership Following Merger                        
--------------------------------------------------------                        

The Company's Certificate of Incorporation authorizes the issuance of 
5,000,000 shares of common stock. As of March 22, 2004, the Company had 813,028 
shares of common stock issued and outstanding and 4,186,972 authorized but      
unissued shares of common stock available for issuance. Although the Company has
no commitments as of this date to issue its securities, the Company will, in all
likelihood, issue a substantial number of additional shares in connection with  
or following an Acquisition. To the extent that additional shares of common     
stock are issued, the Company's stockholders would experience dilution of their 
ownership interests in the Company. Additionally, if the Company issues a       
substantial number of shares of common stock in connection with or following an 
Acquisition, a change in control of the Company may occur which may affect,     
among other things, the Company's ability to utilize net operating loss carry   
forwards, if any. Furthermore, the issuance of a substantial number of shares of
common stock may adversely affect prevailing market prices, if any, for the     
common stock and could impair the Company's ability to raise additional capital 
through the sale of its equity securities. The Company may use consultants and  
other third parties providing goods and services. These consultants or third    
parties may be paid in cash, stock, options or other securities of the Company. 
The Company may in the future need to raise additional funds by selling         
securities of the Company which may involve substantial additional dilution to  
the investors.                                                                  

The Company is Authorized to Issue Preferred Stock                              
--------------------------------------------------                              

RAC's Articles of Incorporation authorizes the designation and issuance of      
1,000,000 shares of preferred stock (the "Preferred Stock"), with such          
designations, powers, preferences, rights, qualifications, limitations and      
restrictions of such series as the Board, subject to the laws of the State of   
Colorado, may determine from time to time. Accordingly, the Board is empowered, 
without stockholder approval, to designate and issue Preferred Stock with       
dividend, liquidation, conversion, voting or other rights which could adversely 
affect the voting power or other rights of the holders of Common Stock. In      
addition, the Preferred Stock could be utilized, under certain circumstances, as
a method of discouraging, delaying or preventing a change in control. Although  
we do not currently intend to designate or issue any shares of Preferred Stock, 

8 

10KSB
10th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 10th
there can be no assurance that we will not do so in the future. It is likely    
however, that following a merger, new management may issue such preferred stock,
and it is possible that one or more series of preferred stock will be designated
and/or issued in order to effectuate a merger or financing. As of this date, we 
have no outstanding shares of Preferred Stock and we have not designated the    
rights or preferences of any series of preferred stock.                         

The Uncertain Structure of an Acquisition May                                   
Result in Risks Relating to the Market for the Company's Common Stock           
---------------------------------------------------------------------           

The Company may form one or more subsidiary entities to effect an     
Acquisition and may under certain circumstances, distribute the securities of   
subsidiaries to the stockholders of the Company. There cannot be any assurance  
that a market would develop for the securities of any subsidiary distributed to 
stockholders or, if it did, any assurance as to the prices at which such        
securities might trade.                                                         

The Company Expects to Pay No Cash Dividends                                    
--------------------------------------------                                    

The Company presently does not expect to pay dividends. The payment of
dividends, if any, will be contingent upon the Company's revenues and earnings, 
if any, capital requirements, and general financial condition. The payment of   
any dividends will be within the discretion of the Company's then Board of      
Directors. The Company presently intends to retain all earnings, if any, to     
implement its business plan, accordingly, the Board does not anticipate         
declaring any dividends in the foreseeable future.                              

Indemnification of Officers and Directors                                       
-----------------------------------------                                       

     The Company's Certificate of Incorporation provides for the indemnification
of its officers and directors to the fullest extent permitted by the laws of the
State of Colorado. It is possible that the indemnification obligations imposed  
under these provisions could result in a charge against the Company's earnings  
and thereby affect the availability of funds for other uses by the Company.     

Taxation Considerations May Impact the                                          
Structure of an Acquisition and Post-merger Liabilities                         
-------------------------------------------------------                         

Federal and state tax consequences will, in all likelihood, be major  
considerations for the Company in consummating an Acquisition. The structure of 
an Acquisition or the distribution of securities to stockholders may result in  
taxation of the Company, the Target or stockholders. Typically, these           
transactions may be structured to result in tax-free treatment to both          
companies, pursuant to various federal and state tax provisions. The Company    
intends to structure any Acquisition so as to minimize the federal and state tax
consequences to both the Company and the Target. Management cannot assure that  
an Acquisition will meet the statutory requirements for a tax-free              
reorganization, or that the parties will obtain the intended tax-free treatment 
upon a transfer of stock or assets. A non-qualifying reorganization could result
in the imposition of both federal and state taxes, which may have an adverse    
effect on both parties to the transaction.                                      

9 

10KSB
11th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 11th
The Company May Be Deemed an Investment                                         
Company and Subjected to Related Restrictions                                   
---------------------------------------------                                   

     The regulatory scope of the Investment Company Act of 1940, as amended (the
"Investment Company Act"), which was enacted principally for the purpose of     
regulating vehicles for pooled investments in securities, extends generally to  
companies engaged primarily in the business of investing, reinvesting, owning,  
holding or trading in securities. The Investment Company Act may, however, also 
be deemed to be applicable to a company which does not intend to be             
characterized as an investment company but which, nevertheless, engages in      
activities which may be deemed to be within the definitional scope of certain   
provisions of the Investment Company Act. The Company believes that its         
Investment Strategy may subject the Company to regulation under the Investment  
Company Act. If the Company is deemed to be an investment company, the Company  
may be forced to divest its investments or become subject to certain            
restrictions relating to the Company's activities, including restrictions on the
nature of its investments and the issuance of securities. In addition, the      
Investment Company Act imposes certain requirements on companies deemed to be   
within its regulatory scope, including registration as an investment company,   
adoption of a specific form of corporate structure and compliance with certain  
burdensome reporting, record keeping, voting, proxy, disclosure and other rules 
and regulations. In the event of the characterization of the Company as an      
investment company, the failure by the Company to satisfy such regulatory       
requirements, whether on a timely basis or at all, would, under certain         
circumstances, have a material adverse effect on the Company.                   

Investors Should Not Rely on Forward-Looking                                    
Statements Because They Are Inherently Uncertain                                
------------------------------------------------                                

This document contains certain forward looking statements that involve
risks and uncertainties. We use words such as "anticipate," "believe," "expect,"
"future," "intend," "plan," and similar expressions to identify forward-looking 
statements. These statements are only predictions. Although we believe that the 
expectations reflected in these forward-looking statements are reasonable, we   
cannot guarantee future results, levels of activity, performance or             
achievements. You should not place undue reliance on these forward-looking      
statements, which apply only as of the date of this document. Our actual results
could differ materially from those anticipated in these forward-looking         
statements for many reasons, including the risks faced by us and described on   
the preceding pages and elsewhere in this document.                             

We believe it is important to communicate our expectations to our     
investors. However, there may be events in the future that we are not able to   
predict accurately or over which we have no control. The risk factors listed    
above, as well as any cautionary language in this document, provide examples of 
risks, uncertainties and events that may cause our actual results to differ     
materially from the expectations we describe in our forward-looking statements. 
Before you invest in our common stock, you should be aware that the occurrence  
of the events described in these risk factors and elsewhere in this document    
could have a material adverse effect on our business, operating results,        
financial condition and stock price.                                            

10

10KSB
12th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 12th
ITEM 2. PROPERTIES                                                              

   On January 5, 2004, the Company relocated its offices from 10 South
Street, Suite 202, Ridgefield, Connecticut, 06877 to 100 Mill Plain Road,       
Danbury, Connecticut 06811. Additionally, the Company's telephone has been      
changed to (203) 791-3871. The Company is using a portion of the premises       
occupied by Catalyst Financial LLC, a full service brokerage, investment banking
and consulting firm, located at 100 Mill Plain Road, Danbury, Connecticut 06811.
Steven N. Bronson, the President of the Company, is the principal and owner of  
Catalyst Financial LLC. Catalyst Financial LLC has agreed to waive the payment  
of any rent by the Company for use of the offices.                              

Prior to January 5, 2004, the Company used a portion of the premises  
located at 10 South Street, Suite 202, Ridgefield, Connecticut 06877, occupied  
by Catalyst Financial LLC. The Company did not pay any rent to Catalyst         
Financial LLC for the use of the offices located at 10 South Street, Suite 202, 
Ridgefield, Connecticut 06877.                                                  

ITEM 3. LEGAL PROCEEDINGS                                                       

     There are no pending legal proceedings to which the Company is a party or
of which any of its property is the subject as of the date of this report and   
there were no such proceedings during the fiscal years ended December 31, 2003  
and December 31, 2002.                                                          

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS                     

      No matter was submitted to a vote of the Company's security holders during
the fourth quarter of the year ended December 31, 2003.                         

 PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS                

         (a) MARKET INFORMATION. The Company's common stock is quoted on the OTC
(Over-The-Counter) Bulletin Board and traded under the symbol ("RDGA"). The     
following table sets forth the range of high and low closing bid prices for the 
Company's common stock for the periods indicated. These prices represent        
reported transactions between dealers that do not include retail markups,       
markdowns or commissions, and do not necessarily represent actual transactions. 

COMMON STOCK
    ------------------------------------------------------------------
   Year/Fiscal Period              High Bid ($)          Low Bid ($)
   ------------------              ------------          -----------
2003                                                      
    First Quarter                       1.50                      1.50
    Second Quarter                      1.50                      1.50
    Third Quarter                       1.50                       .75
    Fourth Quarter                       .75                       .52

2002                                                      
    First Quarter                       3.50                      2.05
    Second Quarter                      2.50                      2.00
    Third Quarter                       2.05                      1.25
    Fourth Quarter                      2.00                      1.25

     As of March 22, 2003, the bid and ask price of the Company's common
stock was $.85.                                                                 

11

10KSB
13th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 13th
      (b) HOLDERS. As of March 22, 2004, the Company had approximately 659
shareholders of record of its common stock, $0.10 par value.                    

   (c) DIVIDENDS. The Company has not declared cash dividends on its
common stock since its inception, and the Company does not anticipate paying any
dividends in the foreseeable future. There are no contractual restrictions on   
the Company's ability to pay dividends.                                         

Recent Sales of Unregistered Securities                                         

     During the fiscal year ended December 31, 2003, the Company did not
issue any shares of common stock                                                

       The following information relates to sales of unregistered securities
by the Company during the fiscal year ended December 31, 2003. All of these     
sales of securities were made in reliance upon an exemption from the            
registration provisions of the Securities Act of 1933 set forth in Sections     
4(2), 4(6) and/or 3(b) thereof and the rules and regulations under the          
Securities Act of 1933, including Regulation D, as transactions by an issuer not
involving any public offering and/or sales to a limited number of purchasers who
were acquiring such securities for their own account for investment purposes and
not with a view to the resale or distribution thereof.                          

         On March 21, 2003, the Board of Directors issued an option to Steven N.
Bronson to purchase 150,000 shares of common stock of the Company at a purchase 
price of $1.65, which was equal to 110% of the closing bid price on March 21,   
2003 (the "Option"), and is exercisable for a period of 5 years. The Option was 
issued to Mr. Bronson as consideration for the services he rendered to the      
Company as the Chairman and President. The Option was issued to Mr. Bronson     
pursuant to Section 4 (2) of the Securities Act of 1933.                        

Section 15(g) of the Exchange Act                                               

   The Company's shares are covered by Section 15(g) of the Securities
Exchange Act of 1934, as amended, and Rules 15g-1 through 15g-6 promulgated     
thereunder, which impose additional sales practice requirements on              
broker-dealers who sell our securities to persons other than established        
customers and accredited investors.                                             

Rule 15g-2 declares unlawful any broker-dealer transactions in  
pennystocks unless the broker-dealer has first provided to the customer a       
standardized disclosure document.                                               

        Rule 15g-3 provides that it is unlawful for a broker-dealer to engage in
a penny stock transaction unless the broker-dealer first discloses and          
subsequently confirms to the customer the current quotation prices or similar   
market information concerning the penny stock in question.                      

Rule 15g-4 prohibits broker-dealers from completing penny stock 
transactions for a customer unless the broker-dealer first discloses to the     
customer the amount of compensation or other remuneration received as a result  
of the penny stock transaction.                                                 

Rule 15g-5 requires that a broker-dealer executing a penny stock
transaction, other than one exempt under Rule 15g-1, disclose to its customer,  
at the time of or prior to the transaction, information about the sales person's
compensation.                                                                   

     The Company's common stock may be subject to the foregoing rules. The
application of the penny stock rules may affect our stockholder's ability to    
sell their shares because some broker-dealers may not be willing to make a      
market in our common stock because of the burdens imposed upon them by the penny
stock rules.                                                                    

12

10KSB
14th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 14th
ITEM 6.      PLAN OF OPERATION                                                  

  The following plan of operation provides information which the Company's
management believes to be relevant to an assessment and understanding of the    
Company's results of operations and financial condition. This discussion should 
be read together with the Company's financial statements and the notes to       
financial statements, which are included in this report.                        

Disclosure Regarding Forward Looking Statements                                 
-----------------------------------------------                                 

    Except for historical information contained herein, the statements in this
report are forward-looking statements that are made pursuant to the safe harbor 
provisions of the Private Securities Litigation Reform Act of 1995. You can     
identify these forward-looking statements when you see words such as "expect,"  
"anticipate," "estimate," "may," "believe," and other similar expressions. These
statements are not guarantees of future performance and are subject to certain  
risks, uncertainties and assumptions that are difficult to predict. Actual      
results could differ materially from those projected in the forward-looking     
statements. Forward-looking statements involve known and unknown risks and      
uncertainties, which may cause the Company's actual results in future periods to
differ materially from forecasted results. These and other risks are described  
elsewhere herein and in the Company's other filings with the Securities and     
Exchange Commission.                                                            

Acquisition Strategy                                                            
--------------------                                                            

 The Company's plan of operation is to arrange for a merger,
acquisition, business combination or other arrangement by and between the       
Company and a viable operating entity. The Company has not identified a viable  
operating entity for a merger, acquisition, business combination or other       
arrangement, and there can be no assurance that the Company will ever           
successfully arrange for a merger, acquisition, business combination or other   
arrangement by and between the Company and a viable operating entity.           

          The Company anticipates that the selection of a business opportunity
will be a complex process and will involve a number of risks, because           
potentially available business opportunities may occur in many different        
industries and may be in various stages of development. Due in part to depressed
economic conditions in a number of geographic areas, rapid technological        
advances being made in some industries and shortages of available capital,      
management believes that there are numerous firms seeking either the limited    
additional capital which the Company will have or the benefits of a publicly    
traded corporation, or both. The perceived benefits of a publicly traded        
corporation may include facilitating or improving the terms upon which          
additional equity financing may be sought, providing liquidity for principal    
shareholders, creating a means for providing incentive stock options or similar 
benefits to key employees, providing liquidity for all shareholders and other   
factors.                                                                        

    In some cases, management of the Company will have the authority to effect
acquisitions without submitting the proposal to the shareholders for their      
consideration. In some instances, however, the proposed participation in a      
business opportunity may be submitted to the shareholders for their             
consideration, either voluntarily by the Board of Directors to seek the         
shareholders' advice and consent, or because of a requirement of state law to do
so.                                                                             

13

10KSB
15th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 15th
    In seeking to arrange a merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity,           
management's objective will be to obtain long-term capital appreciation for the 
Company's shareholders. There can be no assurance that the Company will be able 
to complete any merger, acquisition, business combination or other arrangement  
by and between the Company and a viable operating entity.                       

The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable        
operating entity, although there is no assurance that the Company will be able  
to obtain such additional funds, if needed. Even if the Company is able to      
obtain additional funds there is no assurance that the Company will be able to  
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.                                                  

Competition of RAC's Acquisition Strategy                                       

   In connection with its Acquisition Strategy, the Company expects to
encounter intense competition from other entities having business objectives    
similar to those of the Company. Many of these entities, including venture      
capital firms, blind pool companies, large industrial and financial             
institutions, small business investment companies and wealthy individuals, are  
well-established and have extensive experience in connection with identifying   
and effecting acquisitions directly or through affiliates. Many of these        
competitors possess greater financial, technical, human and other resources than
the Company and there can be no assurance that the Company will have the ability
to compete successfully with such entities. The Company's financial resources   
will be limited in comparison to those of many of its competitors. The Company's
limited financial resources may compel the Company to select certain less       
attractive acquisition prospects.                                               

Investment Strategy                                                             
-------------------                                                             

  On August 25, 2003, the Board of Directors of the Company authorized the
Company to invest a portion of the Company's cash in marketable securities in an
effort to realize a greater rate of return then the Company is currently earning
in light of historically low interest rates. The Board directed that management 
maintain at least $40,000 of the Company's cash in a federally insured bank or  
money market account.                                                           

  In furtherance of the Company's investment strategy the Company opened a
brokerage account with Catalyst Financial LLC ("Catalyst"), a broker-dealer     
registered with the U.S. Securities and Exchange Commission and a member in good
standing with the National Association of Securities Dealers, Inc. Catalyst is  
owned and controlled by Steven N. Bronson, the Company's Chairman and Chief     
Executive Officer. Catalyst has agreed to charge the Company commissions of no  
more that $.02 per share with a minimum of $75 per trade on securities          
transactions. The Board approved the commission structure to be charged by      
Catalyst. Mr. Bronson abstained from voting on all Board resolutions concerning 
the Company's investment strategy and the Company's arrangements with Catalyst. 

      On October 14, 2003, the Company deposited $250,000 in a brokerage
account with Catalyst. As of December 31, 2003, the Company owned securities    
value at $49,580 and an unrealized loss of $2,095). The Company's investment in 
securities is subject to all of the risks associated with equity investing,     
including a loss of monies invested. There can be no assurance that the Company 
will be able to obtain a profitable return on its investments.                  

14

10KSB
16th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 16th
Results of Operations                                                           
---------------------                                                           

    During the year ended December 31, 2003 ("Fiscal 03"), the Company
earned no revenues from operation and generated interest income of $3,077,      
compared to no revenues from continuing operations and interest income in the   
amount of $7,705 for the year ended December 31, 2002 ("Fiscal 02").            

        During Fiscal 03, the Company incurred expenses of $89,616, a decrease
of $122,225 compared to expenses of $211,841 for Fiscal 02. On December 31,     
2003, the Company had invested $49,580 in accordance with its Investment        
Strategy, and as of that date the Company had an unrealized loss of $2,095 based
on its investment in securities.                                                

        For Fiscal 03 the Company incurred a net loss of $86,787 compared to a
net loss of $204,136 for Fiscal 02.                                             

Liquidity and Capital Resources                                                 
-------------------------------                                                 

        During Fiscal 03, the Company satisfied its working capital needs from
cash on hand at the beginning of the year and cash generated from interest      
income during the year. As of December 31, 2003, the Company had working capital
of $185,221. While this working capital will satisfy the Company's immediate    
financial needs, it may not be sufficient to provide the Company with sufficient
capital to finance a merger, acquisition or business combination between the    
Company and a viable operating entity or the development and the exploitation of
the Patent. The Company may need additional funds in order to complete a merger,
acquisition or business combination between the Company and a viable operating  
entity. The Company or the Subsidiary may also need additional funds to finance 
the development and exploitation of the Patent. There can be no assurances that 
the Company will be able to obtain additional funds if and when needed.         

      The Company's future financial condition will be subject to: (1) its
ability to arrange for a merger, acquisition or a business combination with an  
operating business on favorable terms that will result in profitability, or (2) 
its ability to successfully develop and exploit the Patent. There can be no     
assurance that the Company will be able to do so or, if it is able to do so,    
that the transaction will be on favorable terms not resulting in an unreasonable
amount of dilution to the Company's existing shareholders.                      

        The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable        
operating entity, although there is no assurance that the Company will be able  
to obtain such additional funds, if needed. Even if the Company is able to      
obtain additional funds there is no assurance that the Company will be able to  
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.                                                  

The Company may need additional funds in order to develop and 
commercially exploit the Patent, although there is no assurance that the Company
will be able to obtain such additional funds, if needed. Even if the Company is 
able to obtain additional funds there is no assurance that the Company will be  
able to develop and commercially exploit the Patent.                            

15

10KSB
17th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 17th
ITEM 7.    FINANCIAL STATEMENTS                                                 

 The financial statements and related notes are included as part of this
report as indexed in the appendix on pages F-1 through F-16.                    

ITEM 8.    CHANGE IN ACCOUNTANTS                                                

      On October 16, 2003, the Company dismissed Wheeler Wasoff, P.C. as its
independent accountants. The reports of Wheeler Wasoff, P.C. on the financial   
statements for the fiscal years ended December 31, 2002 and December 31, 2001   
contained no adverse opinion or disclaimer of opinion and were not modified as  
to audit scope or accounting principles. The report of Wheeler Wasoff, P.C. on  
the financial statements for the fiscal year ended December 31, 2002 contained  
an explanatory paragraph relating to the uncertainty of the Company's ability to
continue as a going concern.                                                    

        On October 16, 2003, the Company engaged Kostin, Ruffkess & Company, LLC
as its new independent accountants. During the two most recent fiscal years and 
through October 16, 2003 the Company has not consulted Kostin, Ruffkess &       
Company, LLC regarding the application of accounting principles to a specified  
transaction, either completed or proposed; or the type of audit opinion that    
might be rendered on the financial statements of the registrant, and neither a  
written report was provided to the Company or oral advice was provided that     
Kostin, Ruffkess & Company, LLC concluded was an important factor considered by 
the Company in reaching a decision as to the accounting, auditing, or financial 
reporting issue.                                                                

       The Board of Directors of the Company, participated in and approved the
decision to change independent accountants. The Company filed a current report  
on Form 8-K on October 20, 2003, disclosing the change of independent auditors, 
and such report is incorporated herein by reference.                            

Item 8A.  CONTROLS AND PROCEDURES                                               

        Disclosure controls and procedures are controls and other procedures
that are designed to ensure that information required to be disclosed by us in  
the reports that we file or submit under the Exchange Act is recorded,          
processed, summarized and reported, within the time periods specified in the    
Securities and Exchange Commission's rules and forms. Disclosure controls and   
procedures include, without limitation, controls and procedures designed to     
ensure that information required to be disclosed by us in the reports that we   
file under the Exchange Act is accumulated and communicated to our management,  
including our principal executive and financial officer, as appropriate to allow
timely decisions regarding required disclosure.                                 

Evaluation of disclosure and controls and procedures.                           
-----------------------------------------------------                           

        Based on their evaluation of the Company's disclosure controls and
procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities    
Exchange Act of 1934) as of the end of the period covered by this annual report 
on Form 10-KSB the Company's chief executive officer has concluded that the     
Company's disclosure controls and procedures are designed to ensure that        
information required to be disclosed by the Company in the reports that it files
or submits under the Exchange Act is recorded, processed, summarized and        
reported within the time periods specified in the SEC's rules and forms and are 
operating in an effective manner.                                               

16

10KSB
18th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 18th
Changes in internal controls over financial reporting.                          
------------------------------------------------------                          

   There were no changes in the Company's internal controls over
financial reporting or in other factors that have materially affected, or are   
reasonably likely to materially affect, the Company's internal control over     
financial reporting.                                                            

PART III

ITEM 9.  DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;          
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.            

  The following table sets forth the name, age and position of each of our
directors, executive officers and significant employees as of December 31,2000. 
Each director will hold office until the next annual meeting of our stockholders
or until his or her successor has been elected and qualified. Our executive     
officers are appointed by, and serve at the discretion of, the Board of         
Directors.                                                                      

Name                    Age     Position                                        
------------------     -----    --------------------                            
Steven N. Bronson        38     Chairman, Chief Executive Officer and President 
Leonard Hagan            52     Director                                        
Kenneth Schwartz         48     Director                                        

    Steven N. Bronson has served as a director of the Company since June
1996. From September 1998 to August 11, 2000, Mr. Bronson was the sole officer  
of the Company. From September 1998 to March 17, 2000, Mr. Bronson was also the 
sole director of the Company. In September 1996, Mr. Bronson became the Chief   
Executive Officer and President of the Company. Mr. Bronson is also the         
President of Catalyst Financial LLC, a privately held full service securities   
brokerage and investment banking firm. Mr. Bronson has held that position since 
September 24, 1998. During the period of 1991 through September 23, 1998, Mr.   
Bronson was President of Barber & Bronson Incorporated, a full service          
securities brokerage and investment banking firm. In addition, Mr. Bronson is an
officer and director of 4net Software, Inc., a publicly traded corporation.     

     Leonard Hagan has served as a director of the Company since March 17,
2000. Mr. Hagan is a certified public accountant and for the past eight years   
has been a partner at Hagan & Burns CPA's, PC in New York. Mr. Hagan received a 
Bachelors of Arts degree in Economics from Ithaca College in 1974, and earned   
his Masters of Business Administration degree from Cornell University in 1976.  
Mr. Hagan is registered as the Financial and Operations Principal for the       
following broker-dealers registered with the Securities and Exchange Commission:
Adelphia Capital LLC, Mallory Capital Group, LLC, Avalon Partners, Inc., Stacey 
Braun Financial Services, Inc. and Danske Securities (US), Inc. Mr. Hagan is    
also a director of 4net Software, Inc., a publicly traded corporation.          

  Dr. Kenneth Schwartz has served as a director of the Company since March
25, 2000. Dr. Schwartz has been self-employed as a dentist in New York, New     
York. Dr. Schwartz received his Bachelor of Sciences from Brooklyn College in   
1977 and earned his D.D.S. from New York University College of Dentistry in     
1982.                                                                           

17

10KSB
19th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 19th
   No director, executive officer, promoter or control person of the Company
has, within the last five years: (i) had a bankruptcy petition filed by or      
against any business of which such person was a general partner or executive    
officer either at the time of the bankruptcy or within two years prior to that  
time; (ii) been convicted in a criminal proceeding or is currently subject to a 
pending criminal proceeding (excluding traffic violations or similar            
misdemeanors); (iii) been subject to any order, judgment or decree, not         
subsequently reversed, suspended or vacated, of any court of competent          
jurisdiction, permanently or temporarily enjoining, barring, suspending or      
otherwise limiting his involvement in any type of business, securities or       
banking activities; (iv) been found by a court of competent jurisdiction (in a  
civil action), the Securities and Exchange Commission (the "Commission") or the 
Commodity Futures Trading Commission to have violated a federal or state        
securities or commodities law, and the judgment has not been reversed, suspended
or vacated. There are no family relationships among any directors and executive 
officers of the Company.                                                        

Meetings and Committees of the Board of Directors                               
-------------------------------------------------                               

     During the fiscal year ended December 31, 2003, the Board of Directors held
4 meetings. In view of the Company's lack of operations, during the year ended  
December 31, 2003, the Board of Directors did not have any Committees. During   
the fiscal year ended December 31, 2003, all of the directors then in office    
attended 100% of the total number of meetings of the Board of Directors and the 
Committees of the Board of Directors on which they served.                      

Audit Committee                                                                 
----------------                                                                

      The Audit Committee of the Company consists of Steven N. Bronson and
Leonard Hagan. The functions of the Audit Committee are to recommend to the     
Board of Directors the appointment of independent auditors for the Company and  
to analyze the reports and recommendations of such auditors. The committee also 
monitors the adequacy and effectiveness of the Company's financial controls and 
reporting procedures. The Audit Committee does not meet on a regular basis, but 
only as circumstances require.                                                  

Code of Ethics                                                                  
---------------                                                                 

         At a meeting of the Board of Directors of the Company held on March 25,
2004, Company adopted a Code of Ethics. A copy of the Code of Ethics is attached
hereto as Exhibit 14.                                                           

Section 16(a) Beneficial Ownership Compliance                                   
---------------------------------------------                                   

Section 16(a) of the Exchange Act requires the Company's directors and
executive officers, and persons who own more than 10% of a registered class of  
the Company's equity securities, to file with the SEC initial reports of        
ownership and reports of changes in ownership of common stock and other equity  
securities of the Company. Officers, directors and greater than 10% shareholders
are required by SEC regulations to furnish the Company with copies of all       
Section 16(a) forms they file.                                                  

18

10KSB
20th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 20th
 To the Company's knowledge, based solely upon a review of the copies of
such reports furnished to the Company and written representations that no other 
reports were required, during the year ended December 31, 2003, all Section     
16(a) filing requirements applicable to its officers, directors and greater than
10% beneficial owners were complied with.                                       

ITEM 10.    EXECUTIVE COMPENSATION.                                             

Summary Compensation Table(1)                                                   

    The following summary compensation table sets forth information concerning
the annual and long-term compensation earned by the Company's chief executive   
officer and each of the other most highly compensated executive officers        
(collectively, the "Named Executive Officers").                                 

Name/Position           Fiscal year  Annual Salary   Stock Grants  Option Grants
--------------------------------------------------------------------------------
Steven N. Bronson                                                               
CEO and President          2003       $48,000             0          150,000(2) 
                     2002       $48,000             0              0
                     2001       $48,000(3)          0              0

----------------------                                                          
(1) The Columns designated by the SEC for the reporting of certain bonuses, long
term compensation, including awards of restricted stock, long term incentive    
plan payouts, and all other compensation have been eliminated as no such        
bonuses, awards, payouts, grants or compensation were awarded during any fiscal 
year covered by the table.                                                      

(2) On March 21, 2003, the Company issued an option to Steven N. Bronson to     
purchase 150,000 shares of the Company's common stock at the purchase price of  
$1.65, which was 110% percent of the closing bid price on March 21, 2003 and    
such option is exercisable for a period of 5 years.                             

(3) On March 30, 2001, the Company issued Mr. Bronson 38,400 shares of common   
stock (valued at $1.25 per share on the date of issuance) in lieu of his annual 
salary of forty-eight thousand dollars ($48,000) for the period of March 25,    
2001 through March 24, 2002.                                                    

    Other Plans. The Company does not currently have any bonus, profit
sharing, pension, retirement, stock option, stock purchase, or other            
remuneration or incentive plans in effect.                                      

Long Term Incentive Plan. The Company has no long-term incentive    
plan.                                                                           

19

10KSB
21st Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 21st
Aggregate Option Exercises in Fiscal 2003 and Fiscal Year End Option Values     

        The following table contains certain information regarding stock options
exercised during and options to purchase common stock held as of September 30,  
2003, by each of the Named Executive Officers. The stock options listed below   
were granted without tandem stock appreciation rights. We have no freestanding  
stock appreciation rights outstanding.                                          

                                                        [Enlarge/Download Table]

                     Number                 Number of Securities        Value of Unexercised     
                     Of Shares     (1)      Underlying Unexercised      In-the-Money Options     
Name/                Acquired     Value     Options at Fiscal Year End  at Fiscal Year End       
Position             On Exercise  Realized  Exercised/Unexercised       Exercised/Unexercised (2)
------------------   -----------  --------  --------------------------  ---------------------    
                                                                                                 
Steven N. Bronson                                                                                
    Chairman, CEO                                                                                
     and President        0          0              150,000                      $0              
-------------------                                                                              

(1) Calculated on the basis of $.52 per share, the closing price of the common  
stock on the over-the-counter market on December 31, 2003, less exercise price  
payable for such shares.                                                        

(2) Calculated on the basis of the closing share price of the common stock on   
the over-the-counter market on the date exercised, less the exercise price      
payable for such shares.                                                        

Compensation of Directors                                                       
-------------------------                                                       

  In fiscal year ended December 31, 2002, no cash compensation was paid to
our directors for their services as directors. However, on March 21, 2003, the  
Company issued an option to Steven N. Bronson to purchase 150,000 shares of the 
Company's common stock at the purchase price of $1.65, which was 110% percent of
the closing bid price on March 21, 2003 and such option is exercisable for a    
period of 5 years.                                                              

Employment Contracts                                                            
--------------------                                                            

  On March 24, 2001, the Company entered into an Employment Agreement with
Steven N. Bronson, the President of the Company. The terms of such Employment   
Agreement include the following:                                                

Name                       Title        Salary/Year        Term                 
-----------------------------------------------------------------               
Steven N. Bronson     CEO & President     $48,000         1 year                

   A copy of Mr. Bronson's Employment Agreement is attached as an Exhibit to
the Company's Form 10-QSB for the quarter ended March 31, 2001 and is           
incorporated by reference. On March 21, 2003, the Board of Directors authorized 
the renewal of Mr. Bronson's employment agreement with the Company for another 1
year term. Additionally, on March 21, 2003, the Company issued an option to     
Steven N. Bronson to purchase 150,000 shares of the Company's common stock at   
the purchase price of $1.65, which was 110% percent of the closing bid price on 
March 21, 2003 and such option is exercisable for a period of 5 years.          

   On March 25, 2004, the Board of Directors authorized the renewal of Mr.
Bronson's employment agreement with the Company for another 1 year term.        

20

10KSB
22nd Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 22nd
ITEM 11.    SECURITY OWNERSHIP OF CERTAIN                                       
BENEFICIAL OWNERS AND MANAGEMENT.                       

  The following table sets forth as of March 25, 2003, certain information
regarding the beneficial ownership of the common stock outstanding by (i) each  
person who is known to the Company to own 5% or more of the common stock, (ii)  
each director of the Company, (iii) certain executive officers of the Company   
and (iv) all executive officers and directors of the Company as a group. Unless 
otherwise indicated, each of the stockholders shown in the table below has sole 
voting and investment power with respect to the shares beneficially owned.      
Unless otherwise indicated, the address of each person named in the table below 
is c/o Ridgefield Acquisition Corp., 100 Mill Plain Road, Danbury, Connecticut  
06811.                                                                          

                                                    Number of        Percent
Name and Address      Company Position               Shares owned      of class 
----------------      ----------------               ------------      -------- 
Steven N. Bronson     Chairman, CEO                   734,160(2)(3)      76.2%  
and President                       

Kenneth Schwartz      Director                         22,500(4)           *    

Leonard Hagan         Director                           5,000             *    

All directors and executive officers                                            
as a group (3 persons)                                 761,660           79.1%  
-----------------------------                                                   
* Owns less than 1%                                                             

(1) As used in this table, a beneficial owner of a security includes any person 
who, directly or indirectly, through contract, arrangement, understanding,      
relationship or otherwise has or shares (a) the power to vote, or direct the    
voting of, such security or (b) investment power which includes the power to    
dispose, or to direct the disposition of, such security. In addition, a person  
is deemed to be the beneficial owner of a security if that person has the right 
to acquire beneficial ownership of such security within 60 days.                

(2) Includes options to purchase 150,000 shares of RAC common stock at an       
exercise price of $1.65 per share, and such options are set to expire on March  
21, 2008.                                                                       

(3) This amount does not include 33,500 shares of RAC common stock owned by Mr. 
Bronson's spouse. Mr. Bronson expressly disclaims beneficial ownership of the   
shares owned by his spouse.                                                     

(4) This amount includes 17,500 shares of common stock owned by Dr. Schwartz's  
spouse, and Dr. Schwartz expressly disclaims beneficial ownership of the shares 
owned by his spouse.                                                            

ITEM 12.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.                     

     Steven N. Bronson is the President of Catalyst Financial LLC f/k/a Catalyst
Financial Corp. ("Catalyst"), a full service securities brokerage and investment
banking firm. Since March 25, 1999, the Company has utilized a portion of the   
premises occupied by Catalyst as its executive offices. Due to the reduced level
of the Company's operations, Catalyst has, until further notice, waived the     
payment of rent by the Company. No rent was paid by the Company to Catalyst     
during the fiscal year ended December 31, 2003.                                 

21

10KSB
23rd Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 23rd
Steven N. Bronson is the owner and principal of Catalyst Financial LLC
("Catalyst Financial"), a full service securities brokerage, investment banking 
and consulting firm. The Company entered into a Mergers and Acquisitions        
Advisory Agreement, dated as of November 13, 2001, with Catalyst Financial (the 
"M&A Advisory Agreement"). Pursuant to the M&A Advisory Agreement, Catalyst     
Financial agreed to provide consulting services to 4net Software in connection  
with the Company's search for prospective target companies for mergers,         
acquisitions, business combinations and similar transactions, and, if           
investigation warrants, advising the Company concerning the negotiation of terms
and the financial structure of such transactions. For the services rendered     
pursuant to the M&A Advisory Agreement, Catalyst Financial is entitled to       
receive a fee in the amount of five percent (5%) of the total consideration of  
the specific transaction (the "M&A Fee"). The maximum amount of the M&A Fee is  
$500,000 for any single transaction. The term of the Mergers and Acquisitions   
Advisory Agreement is three years. A copy of the M&A Advisory Agreement is      
attached as an exhibit hereto and is incorporated herein by reference.          

    During the fiscal year ended December 31, 2003, the Company paid Hagan &
Burns CPAs P.C. approximately $270 for accounting services. Leonard Hagan, a    
director of the Company, is a fifty percent (50%) owner of Hagan & Burns CPAs   
P.C.                                                                            

ITEM 13.   EXHIBITS AND REPORTS ON FORM 8-K.                                    

a.        Exhibits                                        

        The following exhibits are hereby filed as part of this Annual Report on
Form 10-KSB or incorporated by reference.                                       

3.1      Articles of Incorporation, incorporated by reference to                
Registration Statement No. 33-13074-D as Exhibit 3.1.         

3.2      Amended Bylaws adopted June 1, 1987, incorporated by reference to      
        Annual Report on Form 10-K for the fiscal year ended December 31, 1987
as Exhibit 3.2.                                               

34      Articles of Amendment to Restated Articles of Incorporation dated March 
    7, 1991. Incorporated by reference to Annual Report on Form 10-K for
fiscal year ended December 31, 1990 as Exhibit 3.4.             

3.5     Articles of Amendment to Restated Articles of Incorporation dated March 
     17, 1999, incorporated by reference to Form 8-K reporting an event of
March 9, 1999.                                                  

10.1    OEM Purchase Agreement dated January 15, 1990, between the Company and  
     Ariel Electronics, Inc. incorporated by reference to Annual Report on
      Form 10-K for the fiscal year ended December 31, 1989 as Exhibit 10.1.

10.2    Form of Convertible Promissory Note, 12/30/93 Private Placement         
        incorporated by reference to Annual Report on Form 10-KSB for the fiscal
year ended December 31, 1993 as Exhibit 10.2.                   

10.3    Form of Non-Convertible Promissory Note, 12/30/93 Private Placement     
        incorporated by reference to Annual Report on Form 10-KSB for the fiscal
year ended December 31, 1993 as Exhibit 10.3.                   

10.4    Form of Note Purchaser Warrant Agreement and Warrant, 12/30/93 Private  
       Placement incorporated by reference to Annual Report on Form 10-KSB for
the fiscal year ended December 31, 1993 as Exhibit 10.4.        

22

10KSB
24th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 24th
10.5    Form of Promissory Note, 4/1/96.                                        

10.6    Form of Security Agreement, 4/1/96.                                     

10.7    Form of Common Stock Purchase Warrant, 4/1/96.                          

10.8    Form of Promissory Note, 7/1/96.                                        

10.9    Form of 4/1/96 Promissory Note Extension, 10/17/96.                     

10.10   Form of Common Stock Purchase Warrant, 10/10/96.                        

10.11   Asset Purchase Agreement with JOT incorporated by reference to Form 8-K 
reporting an event of November 4, 1998, and amendment thereto   
        incorporated by reference to Form 8-K reporting an event of December 15,
1998.                                                           

10.12   Stock Purchase Agreement, between Bio-Medical Automation, Inc.          
and Steven N. Bronson, incorporated by reference to the         
Current Report on Form 8-K filed on April 6, 2000.              

10.13   Employment Agreement between Bio-Medical Automation, Inc. and           
Steven N. Bronson, dated as of March 24, 2001, incorporated by  
reference to Quarterly Report on Form 10-QSB for the quarter    
ended March 31, 2001.                                           

10.14   Mergers and Acquisitions Advisory Agreement, dated as                   
of November 13, 2001, between Bio-Medical Automation, Inc. and  
Catalyst Financial LLC incorporated by reference to the Annual  
Report on Form 10-KSB for the year ended December 31, 2001.     

14*     Code of Ethics                                                          

31*     President's Written Certification Of Financial Statements               
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002       

32*     President's Written Certification Of Financial Statements               
Pursuant to 18 U.S.C. Statute 1350                              

--------------------------------                                                
*    Filed herewith                                                             

b         Reports on Form 8-K.                                  

    On October 20, 2003, the Company filed a current report on Form 8-K,
disclosing the change of independent auditors, and such report is incorporated  
herein by reference.                                                            

        On February 5, 2004, the Company filed a current report on Form 8-K,
disclosing a change of address and telephone number, and such report is         
incorporated herein by reference.                                               

23

10KSB
25th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 25th
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES                                 

Audit Fees.                                                                     
----------                                                                      

          The aggregate fees billed to the Company for professional services
rendered by our current and former principal accountants for the audit of our   
annual financial statements and review of our quarterly financial statements was
$7,321 and $7,052, for fiscal years 2003 and 2002, respectively.                

Audit-Related Fees.                                                             
------------------                                                              

None.                                                   

Tax Fees.                                                                       
--------                                                                        

          The aggregate fees billed to the Company for professional services
rendered by accountants for tax related services is $1,750 for fiscal year 2003,
and $500, for fiscal year 2002.                                                 

All Other Fees.                                                                 
--------------                                                                  

None.                                                                           

       The audit committee approved the engagement of Kostin Rufkess &
Company, LLC in the preparation of the Company's tax returns for fiscal year    
2003.                                                                           

SIGNATURES

    In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant
has duly caused this report to be signed on its behalf by the undersigned,      
thereunto duly authorized.                                                      

Dated: March 29, 2004                                                           

                           RIDGEFIELD ACQUISITION CORP.,
                        a Colorado corporation

                       By: /s/ Steven N. Bronson
                                          ------------------------------------
                                          Steven N. Bronson, CEO and President
                                    Principle Executive Officer as
                                          Registrant's duly authorized officer

24

10KSB
26th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 26th
 Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the          
registrant and in the capacities and on the dates indicated:                    

/s/ Steven N. Bronson                           /s/ Kenneth Schwartz            
----------------------------------         ----------------------------------   
Steven N. Bronson                          Kenneth Schwartz                     
President, Chief Executive                 Director                             
Officer and Chairman                       March 29, 2004                       
of the Board of Directors                                                       
Principal Executive Officer                                                     
March 29, 2004                                                                  

/s/ Leonard Hagan                                                               
---------------------------------                                               
Leonard Hagan                                                                   
Director                                                                        
March 29, 2004                                                                  

25

10KSB
27th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 27th
 EXHIBIT INDEX

The following Exhibits are filed herewith:                                      

Exhibit                                                                         
Number      Description of Document                                             
------      -----------------------                                             
14*         Code of Ethics                                                      

31*        President's Written Certification Of Financial Statements            
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 

32*        President's Written Certification Of Financial Statements            
Pursuant to 18 U.S.C. Statute 1350                        

26

10KSB
28th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 28th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

                                                        [Enlarge/Download Table]

                                                                               Page     
                                                                                        
Independent Auditor's Report for 2003                                         F - 2     

Independent Auditor's Report for 2002                                          F -3     

Consolidated Balance Sheet                                                              
       December 31, 2003                                                      F - 4     

Consolidated Statements of Operations and Comprehensive Loss                            
       Years Ended December 31, 2003 and 2002                                           
       and Cumulative Amounts from January 1, 2000 to December 31, 2003       F - 5     

Consolidated Statements of Stockholders' Equity                                         
       Years Ended December 31, 2003 and 2002                                 F - 6     

Consolidated Statements of Cash Flows                                                   
       Years Ended December 31, 2003 and 2002                                           
       and Cumulative Amounts from January 1, 2000 to December 31, 2003   F - 7 - F - 8 

Notes to Consolidated Financial Statements                               F - 9 -- F - 16

F-1 

10KSB
29th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 29th
INDEPENDENT AUDITOR'S REPORT

To the Board of Directors and Stockholders                                      
Ridgefield Acquisition Corp. and Subsidiary                                     

INDEPENDENT AUDITOR'S REPORT

We have audited the accompanying consolidated balance sheet of Ridgefield       
Acquisition Corp. and Subsidiary (the "Company") as of December 31, 2003 and the
related consolidated statements of operations and comprehensive loss,           
stockholders' equity, and cash flows for the year then ended. These consolidated
financial statements are the responsibility of the Company's management. Our    
responsibility is to express an opinion on these consolidated financial         
statements based on our audit.                                                  

We conducted our audit in accordance with auditing standards generally accepted 
in the United States of America. Those standards require that we plan and       
perform the audit to obtain reasonable assurance about whether the consolidated 
financial statements are free of material misstatement. An audit includes       
examining, on a test basis, evidence supporting the amounts and disclosures in  
the consolidated financial statements. An audit also includes assessing the     
accounting principles used and significant estimates made by management, as well
as evaluating the overall financial statement presentation. We believe that our 
audit provides a reasonable basis for our opinion.                              

In our opinion, the consolidated financial statements referred to above present 
fairly, in all material respects, the financial position of the Company as of   
December 31, 2003 and the results of its operations, changes in stockholders'   
equity, and its cash flows for the year then ended, in conformity with          
accounting principles generally accepted in the United States of America.       

The accompanying consolidated financial statements have been prepared assuming  
that the Company will continue as a going concern. As discussed in Note 2 to the
consolidated financial statements, the Company has no principal operations or   
significant revenue producing activities which raises substantial doubt about   
its ability to continue as a going concern. Management's plans in regard to     
these matters are described in Note 2. The consolidated financial statements do 
not include any adjustments that might result from the outcome of this          
uncertainty.                                                                    

/s/  Kostin, Ruffkess & Company, LLC                                            

Kostin, Ruffkess & Company, LLC                                                 
Farmington, Connecticut                                                         
March 16, 2004                                                                  

 F-2

10KSB
30th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 30th
INDEPENDENT AUDITOR'S REPORT

To the Board of Directors and Stockholders RIDGEFIELD ACQUISITION CORP.         

We have audited the statements of operations, stockholders' equity, and cash    
flows of Ridgefield Acquisition Corp. (a development stage company) for the year
ended December 31, 2002. These financial statements are the responsibility of   
the Company's management. Our responsibility is to express an opinion on these  
financial statements based on our audit.                                        

We conducted our audit in accordance with auditing standards generally accepted 
in the United States of America. Those standards require that we plan and       
perform the audit to obtain reasonable assurance about whether the financial    
statements are free of material misstatement. An audit includes examining, on a 
test basis, evidence supporting the amounts and disclosures in the financial    
statements. An audit also includes assessing the accounting principles used and 
significant estimates made by management, as well as evaluating the overall     
financial statement presentation. We believe that our audit provides a          
reasonable basis for our opinion.                                               

In our opinion, the financial statements referred to above present fairly, in   
all material respects, the results of operations and cash flows of Ridgefield   
Acquisition Corp. (a development stage company) for the year ended December 31, 
2002 in conformity with accounting principles generally accepted in the United  
States of America.                                                              

The accompanying financial statements have been prepared assuming that the      
Company will continue as a going concern. As discussed in Note 2, the Company   
sold substantively all of the assets and related operations of its operating    
segment in 1999. These factors, among others, raise substantial doubt about the 
Company's ability to continue as a going concern. Management's plans in regard  
to these matters are described in Note 2. The financial statements do not       
include any adjustments that might result from the outcome of this uncertainly. 

/s/ Wheeler Wasoff, P.C.

Denver, Colorado                                                                
March 24, 2003                                                                  

 F-3

10KSB
31st Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 31st
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
CONSOLIDATED BALANCE SHEET
 DECEMBER 31, 2003

ASSETS

CURRENT ASSETS                                                                  
   Cash and Cash Equivalents                                       $   246,418
                                                                   -----------

      Total Current Assets                                             246,418
                                                                   -----------

OTHER ASSETS                                                                    

   Investments                                                          49,580
                                                                   -----------

      Total Assets                                                 $   295,998
                                                                   ===========

  LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES                                                             
   Accounts payable and accrued expenses                           $    61,197
                                                                   -----------

      Total Current Liabilities                                         61,197
                                                                   -----------

STOCKHOLDERS' EQUITY                                                            
Preferred stock - $.10 par value; authorized - 1,000,000 shares           
        Issued - none                                                       --
Common stock - $.10 par value; authorized - 5,000,000 shares              
        Issued and outstanding - 813,028 shares                         81,303
  Capital in excess of par value                                     1,595,509
   Accumulated deficit                                                 (947,820)
   Deficit accumulated during the development stage                    (492,096)
   Accumulated other comprehensive loss                                  (2,095)
                                                                   -----------

                                                                       234,801
                                                                   -----------

      Total Liabilities and Stockholders' Equity                   $   295,998
                                                                   ===========

The accompanying notes are an integral part of these consolidated financial     
statements.                                                                     

 F-4

10KSB
32nd Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 32nd
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

                                                        [Enlarge/Download Table]

                                                                            Cumulative    
                                                                            Amounts from  
                                                         Years Ended       January 1, 2000
                                                         December 31,      to December 31,
                                                      2003         2002         2003      
                                                                                          
REVENUES                                                                                  
      Interest income                              $   3,077    $   7,705    $  24,675    
        Realized loss on sale of investments            (248)          --         (248)   
                                                   ---------    ---------    ---------    
        Total Revenues                                 2,829        7,705       24,427    
                                                   ---------    ---------    ---------    

OPERATING EXPENSES                                                                        
    General and administrative                        89,616       81,216      367,174    
    Employee stock options                                --      130,625      130,625    
      Write-off of patent                                 --           --       18,724    
                                                   ---------    ---------    ---------    
       Total Expenses                                 89,616      211,841      516,523    
                                                   ---------    ---------    ---------    

NET LOSS                                             (86,787)    (204,136)    (492,096)   
                                                   ---------    ---------    ---------    

OTHER COMPREHENSIVE LOSS                                                                  
    Unrealized losses on securities                   (2,343)          --       (2,343)   
    Reclassification adjustment for realized loss        248           --          248    
                                                   ---------    ---------    ---------    
    Net unrealized losses on securities               (2,095)          --       (2,095)   
                                                   ---------    ---------    ---------    

OTHER COMPREHENSIVE LOSS                           $ (88,882)   $(204,136)   $(494,191)   
                                                   =========    =========    =========    

NET LOSS PER COMMON SHARE                                                                 
    Basic                                          $   (0.11)   $   (0.25)   $   (0.64)   
                                                   =========    =========    =========    

WEIGHTED AVERAGE NUMBER OF                                                                
    COMMON SHARES OUTSTANDING -                                                           
    Basic                                            813,028      813,028      772,221    
                                                   =========    =========    =========    

The accompanying notes are an integral part of these consolidated financial     
statements.                                                                     

 F-5

10KSB
33rd Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 33rd
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 2003 AND 2002

                                                        [Enlarge/Download Table]

                                                                                                  (Deficit)    Accumulated          
                                                                                                 Accumulated    (Deficit)           
                               Common Stock     Capital in                                          During        Other             
                             -----------------  Excess of      Note      Deferred   Accumulated   Development Comprehensive         
                             Shares    Amount   Par Value   Receivable Compensation  (Deficit)       Stage        Loss      Totals  
                             ------    ------   ---------   ---------- ------------  ---------       -----        ----      ------  
                                                                                                                                    
Balance, December 31, 2001   813,028   $81,303  $1,464,884   $(50,000)   $(11,000)   $(947,820)   $(201,173)   $    --    $ 336,194 
Deferred compensation earned      --        --          --         --      11,000           --           --         --       11,000 
Repayment of note receivable      --        --          --     50,000          --           --           --         --       50,000 
Stock options issued              --        --     130,625         --          --           --           --         --      130,625 
Net loss                          --        --          --         --          --           --     (204,136)        --     (204,136)
                             -------   -------  ----------   --------    --------    ---------    ---------    -------    --------- 

Balance, December 31, 2002   813,028    81,303   1,595,509         --          --     (947,820)    (405,309)        --      323,683 
                             -------   -------  ----------   --------    --------    ---------    ---------    -------    --------- 
Unrealized loss of                                                                                                                  
Comprehensive Income              --        --          --         --          --           --           --     (2,095)      (2,095)
Net Loss                          --        --          --         --          --           --      (86,787)        --      (86,787)
                             -------   -------  ----------   --------    --------    ---------    ---------    -------    --------- 

Balance, December 31, 2003   813,028   $81,303  $1,595,509   $     --    $     --    $(947,820)   $(492,096)   $(2,095)   $ 234,801 
                             =======   =======  ==========   ========    ========    =========    =========    =======    ========= 

The accompanying notes are an integral part of these consolidated financial     
statements.                                                                     

 F-6

10KSB
34th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 34th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
 CONSOLIDATED STATEMENTS OF CASH FLOWS

                                                        [Enlarge/Download Table]

                                                                                                Cumulative     
                                                                                                Amounts from   
                                                                              Years Ended    January 1, 2000 to
                                                                              December 31,       December 31,  
                                                                           2003          2002        2003      
                                                                                                               
CASH FLOWS FROM OPERATING ACTIVITES                                                                            
     Net loss                                                           $ (86,787)   $(204,136)   $(492,096)   
     Adjustments to reconcile net loss to net cash used by                                                     
        operating activities:                                                                                  
          Stock issuance for salary                                            --       11,000       96,000    
          Stock issuance for professional services                             --           --       18,200    
          Stock options compensation                                           --      130,625      130,625    
          Realized loss on investment                                         248           --          248    
          Write-off of patent                                                  --           --       18,724    

     Changes in assets and liabilities                                                                         
          Decrease (increase) in note and interest receivable                  --       52,262       50,000    
          Increase (decrease) in accounts payable and accrued expenses     38,715       14,803       45,804    
                                                                        ---------    ---------    ---------    

     Net cash provided by (used) in operating activities                  (47,824)       4,554     (132,495)   
                                                                        ---------    ---------    ---------    

CASH FLOWS FROM INVESTING ACTIVITIES                                                                           
           Purchases of investments                                      (111,955)          --     (111,955)   
           Proceeds from sales of investments                              60,032           --       60,032    
                                                                        ---------    ---------    ---------    

     Net cash used in investing activities                                (51,923)          --      (51,923)   
                                                                        ---------    ---------    ---------    

CASH FLOWS FROM FINANCING ACTIVITIES                                                                           
     Exercise of common stock warrants                                         --           --        5,625    
                                                                        ---------    ---------    ---------    

     Net cash provided by financing activities                                 --           --        5,625    
                                                                        ---------    ---------    ---------    

NET (DECREASE) INCREASE IN CASH                                                                                
AND CASH EQUIVALENTS                                                      (99,747)       4,554     (178,793)   

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIODS                           346,165      341,611      425,211    
                                                                        ---------    ---------    ---------    

CASH AND CASH EQUIVALENTS, END OF PERIODS                               $ 246,418    $ 346,165    $ 246,418    
                                                                        =========    =========    =========    

The accompanying notes are an integral part of these consolidated financial     
statements.                                                                     

F- 7

10KSB
35th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 35th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
 CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
YEARS ENDED DECEMBER 31, 2003 AND 2002 AND
CUMULATIVE AMOUNTS FROM JANUARY 1, 2000 TO DECEMBER 31, 2003

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES            

During the year ended December 31, 2002, the Company charged to equity the      
$130,625 value of employee stock options issued to the Company's President.     

The accompanying notes are an integral part of these consolidated financial     
statements.                                                                     

F- 8

10KSB
36th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 36th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                             

ORGANIZATION                                                  

      Ridgefield Acquisition Corp. (formerly Bio-Medical Automation, Inc.)
 (the "Company") was incorporated under the laws of the State of
   Colorado on October 13, 1983. The Company had been engaged in the
   design, manufacture and marketing of robotic workstations for the
     electronics industry, including routing and depaneling workstations
    predominately to entities in North America and the Pacific Rim. In
         November 1998 the Company entered into an Asset Purchase Agreement (the
       "JOT Agreement") with JOT Automation, Inc. (JOT) a wholly owned Texas
         subsidiary of JOT Automation Group OYJ, a Finnish corporation. Pursuant
      to the agreement, the Company sold JOT all of its assets relating to
      its depaneling and routing business in exchange for $920,000 and the
  assumption of the operating liabilities related to the Company's
business assets. The sale was completed on March 9, 1999.     

        Subsequent to the sale to JOT, the Company's sole continuing operation
  was the continuation of research and development activities on a
  prototype micro-robotic device to manipulate organ tissues on an
       extremely small scale. The Company had filed for a patent application
     for the device. As of December 31, 1999, the Company's research and
development activities for the device were suspended, pending 
assessment of the economic benefit of continuing research and 
        development activities or sale of the patent, as well as assessment of
         other corporate opportunities. In June 2000, the Company determined not
        to pursue further development or sale of the proto-type device and has
written-off the associated patent costs.                      

        On January 14, 2003, in connection with its reinstatement as an active
         corporation in the State of Colorado, the Company changed its name from
 Bio-Medical Automation, Inc. to Ridgefield Acquisition Corp. On
         February 27, 2003, the Board of Directors of the Company authorized the
      formation of a Nevada corporation named Bio-Medical Automation, Inc.
        and authorized the management of the Company to transfer the Company's
        right title and interest in its patent to Bio-Medical Automation, Inc.
        On March 3, 2003, the Company filed Articles of Incorporation with the
Secretary of State of the State of Nevada to form Bio-Medical 
     Automation, Inc., a Nevada corporation wholly owned by the Company.

     Commencing January 1, 2000, the Company is considered a development
         stage company as defined by Statement of Financial Accounting Standards
     (SFAS) No.7, as it has no principal operations nor revenue from any
source.                                                       

PRINCIPLES OF CONSOLIDATION                                   

       The consolidated financial statements of Ridgefield Acquisition Corp.
        include the accounts of Bio-Medical Automation, Inc., its wholly owned
   subsidiary. All intercompany transactions have been eliminated in
consolidation.                                                

INCOME TAXES                                                  

     The Company has adopted the provisions of SFAS 109, "Accounting for
Income Taxes". SFAS 109 requires recognition of deferred tax  
    liabilities and assets for the expected future tax consequences of
   events that have been included in the financial statements or tax
         returns. Under this method, the deferred tax liabilities and assets are
        determined based on the difference between the financial statement and
       tax basis of assets and liabilities using enacted tax rates in effect
for the year in which the differences are expected to reverse.

 F-9

10KSB
37th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 37th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                 

LOSS PER COMMON SHARE                                         

       Basic loss per common share is calculated by dividing net loss by the
       weighted average number of common shares outstanding during the year.
        Diluted income per common share is calculated by adjusting outstanding
     shares, assuming conversion of all potentially dilutive convertible
         equity instruments consisting of options. There is no difference in the
calculation of basic and diluted loss per share for any period
      presented because there are no common stock equivalents. Convertible
      equity instruments are not considered in the calculation of loss per
share, as their inclusion would be antidilutive.              

CASH EQUIVALENTS                                              

     For purposes of reporting cash flows, the Company considers as cash
    equivalents all highly liquid investments with a maturity of three
months or less at the time of purchase.                       

USE OF ESTIMATES                                              

       The preparation of financial statements in conformity with accounting
        principles generally accepted in the United States of America requires
       management to make estimates and assumptions that affect the reported
       amounts of assets and liabilities and disclosure of contingent assets
      and liabilities at the date of the financial statements and reported
      amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.                    

STOCK BASED COMPENSATION                                      

        The company accounts for its stock-based compensation using Accounting
Principles Board's Opinion No. 25 ("APB 25"). Under APB 25,   
       compensation expense is recognized for stock options with an exercise
   price that is less than the market price on the grant date of the
       option. For stock options with exercise prices at or above the market
value of the stock on the grant date, the Company adopted the 
     disclosure-only provisions of SFAS 123, "Accounting for Stock-Based
       Compensation." The Company has adopted the disclosure-only provisions
 of SFAS 123, for the stock options granted to the employees and
    directors of the Company. In 2003, the Company issued an option to
      Steven N. Bronson to purchase 150,000 shares of the Company's common
     stock at the purchase price of $1.65, which was 110% percent of the
        closing bid price on March 21, 2003 and such option is exercisable for
   a period of 5 years. In 2002, the Company recognized compensation
    expense of $130,625 for options granted to its President below the
market price, based on the difference                         

F-10

10KSB
38th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 38th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                 

       between the exercise price and market price on the date of grant. Had
       compensation expense for the options granted been determined based on
       the fair value at the grant date for the options, consistent with the
       provisions of SFAS 123, the Company's net loss and net loss per share
for the years ended December 31, 2003 and 2002 would have been
increased to the pro forma amounts indicated below:           

                                              2003              2002
Net loss                    
                          As reported       $ (86,787)       $ (204,136)
                          Pro forma          (230,097)         (220,126)

Net loss per share          
                          As reported            (.11)             (.25)
                          Pro forma              (.28)             (.27)

       The fair value of each option grant is estimated on the date of grant
 using the Black-Scholes option-pricing model with the following
         assumptions used for grants in fiscal 2003 and 2002: no dividend yield;
         expected volatility of 90%; risk-free interest rate of 3%; and expected
life of five years for 2003 and one year for 2002.            

PATENT COSTS                                                  

        The Company had applied for a patent from the U.S. Patent Office for a
   micro-robotic device under development. The costs associated with
      obtaining this patent were capitalized and were to be amortized over
        the life of the patent of seventeen years upon issuance of the patent.

      The patent was the Company's sole asset of continuing operations. In
      1999, the Company incurred research and development costs associated
        with development of the micro-robotic device underlying the patent and
        had, as of December 31, 1999, continued to assess the economic benefit
  of continuing research and development activities or sale of the
patent.                                                       

In February 2000, the Company entered into an agreement with a
       shareholder which resulted in a change in control of the Company. The
         agreement specified that the Company owns certain intellectual property
       consisting of the patent application and a related Technology License
 Agreement. In June 2000, the Company decided not pursue further
        research and development or sale of the patent and has written-off the
capitalized costs.                                            

       In 2002, the Company received its patent for the micro-robotic device
from the U.S. Patent Office.                                  

F-11

10KSB
39th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 39th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                 

FAIR VALUE                                                    
The carrying amount reported in the balance sheet for cash,   
         investments, accounts payable and accrued liabilities approximates fair
value because of the immediate or short-term maturity of these
financial instruments.                                        

CONCENTRATIONS OF CREDIT RISK                                 

Financial instruments which potentially subject the Company to
    concentrations of credit risk consist principally of cash and cash
       equivalents. The Company maintains cash and cash equivalents accounts
       at two financial institutions. The Company periodically evaluates the
 credit worthiness of financial institutions, and maintains cash
     accounts only in large high quality financial institutions, thereby
 minimizing exposure for deposits in excess of federally insured
   amounts. At December 31, 2003 cash in excess of federally insured
amounts was approximately $98,198.                            

RECENT ACCOUNTING PRONOUNCEMENTS                              

In December 2002, the FASB approved SFAS 148, "Accounting for 
        Stock-Based Compensation - Transition and Disclosure - an amendment of
    FASB Statement No. 123." SFAS 148 amends SFAS 123, "Accounting for
        Stock-Based Compensation" to provide alternative methods of transition
         for a voluntary change to the fair value based method of accounting for
     stock-based employee compensation. In addition, SFAS 148 amends the
         disclosure requirements of SFAS 123 to require prominent disclosures in
  both annual and interim financial statements about the method of
        accounting for stock-based employee compensation and the effect of the
      method used on reported results. SFAS 148 is effective for financial
         statements for fiscal years ending after December 15, 2002. The Company
         will continue to account for stock-based compensation using the methods
detailed in the stock-based compensation accounting policy.   

     SFAS 149, "Amendment to Statement 133 on Derivative Instruments and
       Hedging Activities" ("SFAS 149"), addresses certain decisions made by
     the Financial Accounting Standards Board as part of the Derivatives
     Implementation Group process. In general, SFAS 149 is effective for
        contracts entered into or modified after June 30, 2003 and for hedging
relationships designated after June 30, 2003.                 

SFAS 150, "Accounting for Certain Financial Instruments with  
         Characteristics of Both Liabilities and Equity" ("SFAS 150"), addresses
     how an issuer classifies and measures certain financial instruments
        with characteristics of both liabilities and equity. The provisions of
  SFAS 150 are effective for financial instruments entered into or
        modified after May 31, 2003, and otherwise are effective July 1, 2003.

         The adoption of SFAS 149 and SFAS 150 did not have a material impact on
the financial position, results of operations or cash flows.  

 F- 12

10KSB
40th Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 40th
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - BASIS OF ACCOUNTING                                                    

       The accompanying financial statements have been prepared on the basis
of accounting principles applicable to a going concern which  
contemplates the realization of assets and extinguishment of  
liabilities in the normal course of business. As shown in the 
  accompanying financial statements, the Company has accumulated a
  deficit of $947,820 through December 31, 1999 and has incurred a
      deficit since reentering the development stage, effective January 1,
       2000, of $492,096. As discussed in Note 1, the Company, in 1999, sold
   all of its assets relating to its historical line of business and
      abandoned, in 2000, its efforts in the research and development of a
   micro-robotic device. As of December 31, 2003, the Company has no
principal operations or revenue producing activities.         

      These factors indicate that the Company may be unable to continue in
  existence. The Company's financial statements do not include any
   adjustments related to the to the carrying value of assets or the
         amount and classification of liabilities that might be necessary should
       the Company be unable to continue in existence. The Company's ability
       to establish itself as a going concern is dependent on its ability to
    merge with another entity or acquire revenue producing activities.

NOTE 3 - INVESTMENTS                                                            

       Investments are classified as available for sale according to the
       provisions of Financial Accounting Standards Board Statement No. 115,
     "Accounting for Certain Investments in Debt and Equity Securities."
   Realized gains and losses are calculated using the original cost.
        Investments at December 31, 2003, are comprised of common stocks which
      had an aggregate cost of $51,675 and a fair market value of $49,580.
    Those investments had net unrealized losses of $2,095 for the year
         ended December 31, 2003. During 2003, the Company sold investments that
  had an aggregate cost of $60,280 and an aggregate sales price of
        $60,032 which resulted in a realized loss of $248. No investments were
held during 2002.                                             

NOTE 4 - STOCKHOLDERS' EQUITY                                                   

COMMON STOCK                                                  

   Common shares issued for non-cash consideration are valued at the
       trading price of the Company's common stock as of the date the shares
were approved for issuance.                                   

F-13

10KSB
41st Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 41st
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - STOCKHOLDERS' EQUITY (CONTINUED)                                       

OPTIONS                                                       

         The status of outstanding options granted by the Company is as follows:

                                                          No.     Weighted Avg
                                                       of       Exercise
                                                     Shares      Price

       Options Outstanding - January 1, 2001          145,000    $  1.15
       (145,000 exercisable)
Granted                                             --    
                                           -------
       Options Outstanding - December 31, 2001        145,000       1.15
       (145,000 exercisable)
       Expired                                       (120,000)      1.13
       Granted                                         95,000       1.13
                                           -------
       Options Outstanding - December 31, 2002        120,000       1.15
                  (120,000) exercisable)   -------

       Expired                                        (120,000)     1.15
       Granted                                         150,000      1.65
                                           -------
       Options Outstanding - December 31, 2003        150,000       1.65
                  (150,000) exercisable)   -------

       The fair value of each option grant is estimated on the date of grant
 using the Black-Scholes option-pricing model with the following
         weighted-average assumptions used for grants in 2003: dividend yield of
     0%; expected volatility of 90%; discount rate of 3.0%; and expected
    life of five years for 2003 and one year for 2002. No options were
exercised or forfeited during 2001.                           

      At December 31, 2003, the number of options exercisable was 150,000,
     the weighted average exercise price of these options was $1.65, the
    weighted average remaining contractual life of the options was 4.3
years and the exercise price was $1.65 per share.             

      At December 31, 2002, the number of options exercisable was 120,000,
     the weighted average exercise price of these options was $1.15, the
         weighted average remaining contractual life of the options was .4 years
and the exercise price was $1.13 to $1.25 per share.          

NOTE 5 - INCOME TAXES                                                           

   At December 31, 2003 and 2002, the Company has net operating loss
carryforwards totaling approximately $1,030,000 and $944,000, 
        respectively, that may be offset against future taxable income through
      2022. Due to the change in control of the Company in March 2000, the
      Company's ability to realize the tax benefits from the net operating
       losses and research and development credits prior to that date may be
significantly limited.                                        

F-14

10KSB
42nd Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 42nd
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 - INCOME TAXES (CONTINUED)                                               

    The Company has fully reserved the tax benefits of these operating
     losses and credits because the likelihood of realization of the tax
    benefits cannot be determined. These carryforwards and credits are
      subject to review by the Internal Revenue Service. The approximately
    $450,000 tax benefit of the loss carryforward has been offset by a
         valuation allowance of the same amount. Of the total tax benefit of the
        loss carryforward, $38,000 and $90,000 is applicable to 2003 and 2002,
respectively.                                                 

       Temporary differences between the time of reporting certain items for
        financial and tax reporting purposes are not considered significant by
management of the Company.                                    

 There is no current or deferred tax expense for the years ended
December 31, 2003 and 2002.                                   

NOTE 6 - RELATED PARTY TRANSACTIONS                                             

         In March 2001, the Company issued 38,400 shares of common stock (valued
         at $1.25 per share) to the President of the Company in lieu of a salary
        of $48,000. At December 31, 2001, the President had earned $37,000 and
the balance of $11,000 was earned in 2002.                    

  In March 2001, the Company loaned the President $50,000 at 6.0%,
        uncollateralized, due March 30, 2003, to exercise warrants to purchase
    50,000 shares of the Company's common stock at $1.00 per share. In
        December 2002, the President of the Company repaid the loan of $50,000
and accrued interest of $5,153.                               

  During 2003 and 2002 the Company incurred approximately $270 and
   $5,000, respectively, in professional fees to a firm managed by a
member of the Board of Directors.                             

       In November 2001, the Company entered into a Mergers and Acquisitions
        Advisory Agreement with Catalyst Financial LLC ("Catalyst"), an entity
      whose owner and principal is the President of the Company. Under the
      terms of the agreement, Catalyst will earn a fee, as outlined in the
       agreement, in the event the Company completes a merger. The agreement
        is for a three year period, terminating November, 2004. As of December
31, 2003, no merger had been completed under the agreement.   

         The President's employment agreement is renewable annually for one year
        at an annual salary of $48,000. During 2003, the President was granted
       an option to purchase 150,000 shares of the Company's common stock at
         an exercise price of 110% of the closing market price as of the date of
grant, for a period of five years.                            

F-15

10KSB
Last Page of 43
TOC
1st
Previous
Next
↓Bottom
Just 43rd
 RIDGEFIELD ACQUISITION CORP. AND SUBSIDIARY
 (Formerly Bio-Medical Automation, Inc.)
 (A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - RELATED PARTY TRANSACTIONS (CONTINUED)                                 

        For the period February 2001 through January 5, 2004, the Company used
  a portion of the premises located at 10 South Street, Suite 202,
      Ridgefield, Connecticut 06877, occupied by Catalyst Financial LLC, a
        full service brokerage, investment banking and consulting firm, as its
       principal office. Steven N. Bronson, the President of the Company, is
        the principal and owner of Catalyst Financial LLC. The Company did not
   pay any rent to Catalyst Financial LLC for the use of the offices
       located at 10 South Street, Suite 202, Ridgefield, Connecticut 06877.
        Since January 5, 2004, for its principal office the Company is using a
        portion of the premises occupied by Catalyst Financial LLC, located at
         100 Mill Plain Road, Danbury, Connecticut 06811. Catalyst Financial LLC
       has agreed to waive the payment of any rent by the Company for use of
         the offices. The Company has not paid any rent for its principal office
for the years ended December 31, 2003 and 2002.               

NOTE 7 - SEGMENT REPORTING                                                      

         In June 1997, SFAS 131, "Disclosure about Segments of an Enterprise and
      Related Information" was issued, which amends the requirements for a
         public enterprise to report financial and descriptive information about
      its reportable operating segments. Operating segments, as defined in
         the pronouncement, are components of an enterprise about which separate
       financial information is available that is evaluated regularly by the
Company in deciding how to allocate resources and in assessing
      performance. The financial information is required to be reported on
      the basis that is used internally for evaluating segment performance
        and deciding how to allocate resources to segments. The Company has no
reportable segments at December 31, 2003 and 2002.            

F-16

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘10KSB’ Filing		Date		First		Last			Other Filings
		3/21/08		22
Filed on:		3/29/04		25		26
		3/25/04		19		21
		3/22/04		1		13
		3/16/04		29
		2/5/04		24
		1/5/04		12		43			8-K
For Period End:		12/31/03		1		43
		10/20/03		17		24
		10/16/03		17					8-K
		10/14/03		4		15
		9/30/03		21					10QSB,  10QSB/A
		8/25/03		4		15			4
		7/1/03		39
		6/30/03		4		39			10QSB
		5/31/03		39
		3/30/03		42
		3/25/03		22
		3/24/03		30
		3/22/03		12
		3/21/03		13		37			4
		3/7/03		4					8-K
		3/3/03		4		36
		2/27/03		36
		1/14/03		2		36			8-K
		1/1/03		2
		12/31/02		2		43			10KSB
		12/15/02		39
		4/1/02		2
		3/24/02		20
		3/19/02		3
		12/31/01		2		42			10KSB40
		11/13/01		23		24
		3/31/01		21		24			10QSB
		3/30/01		20					10KSB40
		3/25/01		20
		3/24/01		21		24
		8/11/00		18
		6/30/00		2		3			10QSB
		4/6/00		24					8-K,  SC 13D/A
		3/25/00		18					8-K
		3/17/00		18
		1/1/00		28		40
		12/31/99		36		40			10KSB
		3/25/99		22
		3/17/99		23
		3/9/99		2		36			8-K,  8-K/A
		12/15/98		24					8-K
		11/4/98		24					8-K
		9/24/98		18
		9/23/98		18
		12/31/93		23
									List all Filings

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/12/24  Ridgefield Acquisition Corp.      10-K       12/31/23   36:2.8M                                   Toppan Merrill/FA2
 2/28/23  Ridgefield Acquisition Corp.      10-K       12/31/22   33:3.4M                                   Toppan Merrill/FA2
 3/11/22  Ridgefield Acquisition Corp.      10-K       12/31/21   33:2.5M                                   Toppan Merrill/FA2
 3/04/21  Ridgefield Acquisition Corp.      10-K       12/31/20   33:1.9M                                   Toppan Merrill/FA